文章核心观点 - 生物技术公司Tiziana Life Sciences宣布其CEO将在第37届年度ROTH会议上进行炉边谈话并主持一对一投资者会议，同时介绍了公司主要候选药物鼻内给药的foralumab的相关情况 [1] 公司动态 - 公司CEO Ivor Elrifi将于2025年3月18日12:00 pm PST / 15:00 pm ET / 19:00 pm GMT进行虚拟炉边谈话，并主持一对一投资者会议，会议于3月16 - 18日在加利福尼亚州丹纳波因特举行 [1][2] - 可联系ROTH代表安排一对一会议，也可在线注册观看网络直播 [2] 候选药物情况 - foralumab是一种完全人源抗CD3单克隆抗体，鼻内给药时可刺激T调节细胞，在非活动性继发性进展型多发性硬化症（na - SPMS）开放标签中期扩大使用（EA）计划中，10名患者用药6个月内疾病均有改善或稳定，FDA允许额外20名患者加入该EA计划 [2] - 鼻内foralumab正在非活动性继发性进展型多发性硬化症患者中进行2a期随机、双盲、安慰剂对照、多中心、剂量范围试验 [2] - foralumab能结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果 [3] 公司介绍 - Tiziana Life Sciences是临床阶段生物制药公司，利用变革性药物递送技术开发突破性疗法，实现免疫疗法的替代给药途径 [4] - 公司创新的鼻腔给药方法与静脉给药相比，在疗效、安全性和耐受性方面有改善潜力 [4] - 公司主要候选药物鼻内foralumab是目前唯一处于临床开发阶段的完全人源抗CD3单克隆抗体，在研究中显示出良好安全性和临床反应 [4] - 公司免疫疗法替代给药途径技术已获专利，多个申请待批，有望实现广泛的产品线应用 [4]

文章核心观点 - 公司重新符合纳斯达克上市最低出价价格要求，证券将继续在纳斯达克上市，同时介绍了公司主要候选药物鼻内给药的福拉珠单抗的情况 [1][2] 公司合规情况 - 2025年1月29日公司被纳斯达克通知不符合最低出价价格上市规则，因其普通股连续30个工作日收盘价未达1美元或以上 [2] - 公司需连续十个交易日保持最低收盘价1美元或以上以重新合规，于2025年3月12日达成，现已重新符合上市规则5550(a)(2) [2] 福拉珠单抗情况 - 福拉珠单抗是全人抗CD3单克隆抗体，鼻内给药可刺激T调节细胞，在非活动性继发性进展型多发性硬化症（na - SPMS）开放标签扩展准入（EA）项目中，10名患者用药6个月内疾病均有改善或稳定，FDA允许额外20名患者加入该EA项目 [3] - 鼻内福拉珠单抗正在非活动性继发性进展型多发性硬化症患者中进行2a期随机双盲安慰剂对照多中心剂量范围试验，该试验于2023年11月开始筛选患者 [3][4] - 福拉珠单抗结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果，鼻内抗CD3单克隆抗体免疫调节是治疗神经炎症和神经退行性人类疾病的新途径 [4] 公司概况 - 公司是临床阶段生物制药公司，利用变革性药物递送技术开发突破性疗法，实现免疫疗法替代给药途径 [5] - 公司创新的鼻腔给药方法与静脉给药相比，在疗效、安全性和耐受性方面有改善潜力 [5] - 公司主要候选药物鼻内福拉珠单抗是目前唯一处于临床开发阶段的全人抗CD3单克隆抗体，在研究中显示出良好安全性和临床反应，其免疫疗法替代给药途径技术已获专利，多个申请待批，有望实现广泛管线应用 [5]

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement i ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating intracerebral hemorrhage or stroke NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclo ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing mic ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery. This collab ...